Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2023/008862MICROORGANISM HAVING WEAKENED ACTIVITY OF LACI FAMILY DNA-BINDING TRANSCRIPTIONAL REGULATOR, AND L-GLUTAMIC ACID PRODUCTION METHOD USING SAME
WO 02.02.2023
Int.Class C12N 15/77
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
77for Corynebacterium; for Brevibacterium
Appl.No PCT/KR2022/010905 Applicant CJ CHEILJEDANG CORPORATION Inventor KWON, Nara
The application relates to a microorganism having weakened activity of a LacI family DNA-binding transcriptional regulator protein, and an L-glutamic acid production method using same. A Corynebacterium sp. microorganism having weakened activity of a LacI family DNA-binding transcriptional regulator protein has remarkably increased L-glutamic acid productivity, and thus the microorganism can produce L-glutamic acid in a yield higher than that of a conventional microorganism by using same.
2.WO/2023/008982ANTI CD154 ANTIBODY AND USE THEREOF
WO 02.02.2023
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/KR2022/011334 Applicant SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION Inventor CHUNG, Jun Ho
The present invention relates to an antibody specifically binding to CD154 and, particularly, to: an antibody comprising HCDR, which comprises amino acid sequences of SEQ ID NOs: 1 to 3, and LCDR which comprises amino acid sequences of SEQ ID NOs: 4 to 6; and a pharmaceutical composition comprising the antibody and a drug, and for preventing or treating a T cell-mediated autoimmune disease or an organ transplant rejection reaction.
3.WO/2023/007182PROTEIN INTERACTION INHIBITORS
WO 02.02.2023
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
Appl.No PCT/GB2022/052007 Applicant THE UNIVERSITY OF BIRMINGHAM Inventor RAYES, Julie
The invention relates to agents for use in preventing or reducing the interaction between S100 A8/A9 and GPIbα. Such agents are particularly for use in treating or preventing one or more inflammatory and/or thrombotic disease, such as cardiovascular diseases, chronic inflammatory diseases, infectious diseases and autoimmune diseases. An agent of the invention may be an antibody, a small molecule inhibitor, a peptide, a polypeptide, a recombinant protein, a nucleic acid, a T-cell receptor (TCR), an affibody, an aptamer, or a glycosaminoglycan.
4.WO/2023/007497LARGE SCALE PURIFICATION OF ANTIBODIES
WO 02.02.2023
Int.Class C07K 16/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
06from serum
Appl.No PCT/IL2022/050818 Applicant ARIEL SCIENTIFIC INNOVATIONS LTD. Inventor PATCHORNIK, Guy
A method of isolating an antibody is disclosed. The method comprises contacting an aggregate comprising a hydrophobic chelator, at least one non-ionic detergent, metal ions and a non-detergent hydrophobic agent with a liquid sample comprising the antibody under conditions that allow partitioning of the antibody into the aggregate, thereby isolating the antibody. Kits for isolating antibodies are also disclosed.
5.WO/2023/010032INTERLEUKIN-2 MUTEINS, FUSION PROTEINS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS
WO 02.02.2023
Int.Class A61K 38/20
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
20Interleukins
Appl.No PCT/US2022/074181 Applicant ANWITA BIOSCIENCES, INC. Inventor ZHONG, Ziyang
Provided herein are interleukin-2 muteins and fusion proteins comprising an interleukin-2 mutein and a half-life-extension domain. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of a proliferative disease.
6.WO/2023/010047MODIFIED T CELL RECEPTORS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS AND CANCER
WO 02.02.2023
Int.Class C07K 14/725
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
725T-cell receptors
Appl.No PCT/US2022/074202 Applicant NANTCELL, INC. Inventor OLSON, Clifford, Anders
Modified T cell receptors, cells comprising the modified T cell receptors, nucleic acids encoding the modified T cell receptors, and methods for using the modified T cell receptors are contemplated. Modified T cell receptor comprising two peptide chains are disclosed herein. The two peptide chains may be the same or different, and each peptide chain comprises an extracellular domain comprising a variable region, a constant region, and a connecting peptide, a transmembrane domain, and an intracellular domain comprising a CD28 region and a CD3 ζ ITAM region. Nucleic acids encoding the modified T cell receptors, and vectors comprising the nucleic acids are also disclosed. Additionally, a method for treating cancer and/or a viral infection is disclosed comprising administering a cell comprising the modified T cell receptor.
7.WO/2023/006117ANTIBODIES AGAINST CLL1 AND CONSTRUCTS THEREOF
WO 02.02.2023
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2022/109528 Applicant NANJING LEGEND BIOTECH CO., LTD. Inventor ZHANG, Yafeng
Provided herein are antibodies and antigen-binding fragment thereof targeting CLL1, and chimeric antigen receptors (e.g., monovalent CAR, and multivalent CAR including bi-epitope CAR) having one or more anti-CLL1 antigen-binding fragments thereof. Further provided are engineered immune effector cells (e.g., T cells) expressing the chimeric antigen receptors and methods of use thereof.
8.WO/2023/008337ANTI-HEPATITIS B VIRUS AGENT TARGETING HOST FACTOR LIPG
WO 02.02.2023
Int.Class A61K 45/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
Appl.No PCT/JP2022/028503 Applicant PUROTECH BIO, INC. Inventor YANAGAWA, Hiroshi
An anti-HBV agent according to the present invention contains, as an active ingredient, a substance which binds to LIPG and inhibits the functions of LIPG. The inventors of the present application have found that LIPG is a factor that plays an important role in the adhesion and uptake of HBV, and has a function as a cofactor, which supports the intracellular invasion of HBV independently of NTCP, and also contributes to the proliferation of HBV in cells. The LIPG-binding substance exhibits an anti-HBV action by: binding, when on the surface of hepatocytes, to LIPG to inhibit the cell adhesion and uptake of HBV; and binding, when delivered into the hepatocytes, to LIPG present in cells to inhibit any step in the intracellular proliferation of HBV.
9.20230029594BODY FAT REDUCING AGENT AND METHOD FOR SCREENING FOR SUBSTANCE CAPABLE OF REDUCING BODY FAT
US 02.02.2023
Int.Class C12Q 1/02
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
02involving viable microorganisms
Appl.No 17788524 Applicant OSAKA UNIVERSITY Inventor Shizuo AKIRA

The present invention provides a body fat reducing agent comprising a Regnase-1 inhibitor as an active ingredient, and a method for screening for a substance capable of reducing body fat, the method comprising selecting a substance capable of inhibiting the expression of Regnase-1 or a substance capable of inhibiting the function of Regnase-1. The body fat reducing agent of the present invention is useful for improving metabolic syndrome, and for preventing and/or treating fatty liver disease, including nonalcoholic steatohepatitis (NASH). The screening method of the present invention can be used to identify a useful substance capable of reducing body fat.

10.20230030983FGFR/PD-1 COMBINATION THERAPY FOR THE TREATMENT OF CANCER
US 02.02.2023
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No 17655519 Applicant ASTEX THERAPEUTICS LTD Inventor Jayaprakash KARKERA

Provided herein are combination therapies for the treatment of cancer. In particular, the disclosed methods are directed to treatment of cancer in a patient comprising administering an antibody that blocks the interaction between PD-1 and PD-L1 and an FGFR inhibitor, wherein the antibody that blocks the interaction between PD-1 and PD-L1 and the FGFR inhibitor are administered if one or more FGFR variants are present in a biological sample from the patient.